Overview
Investment Type
Venture Capital
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 17, 2012 | Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised $32 million in a Series C round. Among the company’s institutional investors are Clarus Ventures, HealthCare Ventures, Quaker Partners, Novi... |
| Oct 5, 2012 | Early Stage East: 25 startups pitch at 15th year of regional showcase [VIDEO] | It wasn’t quite ABC’s “Shark Tank,” but it was as close as you could get without the cameras. Moderated by Shark Tank star and FUBU founder Daymond John, 25 companies pitched in front of a room of 120 investors, attorneys and accountants at... |
| Oct 12, 2009 | Pittsburgh’s Cellumen brings total 2009 fund-raise to $1.3 million | Cellumen’s primary investors are Safeguard Scientifics, which says it owns 41 percent of Cellumen, and Novatis Capital. Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from l... |
| Mar 31, 2009 | Pittsburgh’s Cellumen wants to raise $2.5 million | Cellumen has raised about $10 million since 2004 – the bulk of that coming through an $8.7 million Series B investment (pdf) in July 2007. Its primary investors are Safeguard Scientifics, which says it owns 41 percent of Cellumen, and Nova... |
| Pittsburgh’s Cellumen wants to raise $2.5 million | PITTSBURGH, Pennsylvania — Pittsburgh-based Cellumen Inc. wants to raise $2.5 million through debt, a warrant or convertible debt, according to a filing made in February with the Securities and Exchange Commission. It will not offer equity... | |
| Pittsburgh’s Cellumen brings total 2009 fund-raise to $1.3 million | PITTSBURGH, Pennsylvania — Drug analysis company Cellumen has raised about $700,000, bringing their total 2009 fund-raising to $1.3 million, according to a filing last week with the Securities and Exchange Commission. The company had hoped ... | |
| Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | A company with a small molecule cancer treatment to combat solid tumor cancers as well as hematological malignancies has raised $5 million in a combination of debt, options and warrants, according to a Form D filing with the Securities and ... |
Reviews 0
FAQ about Novitas Capital
What has the press written about Novitas Capital?
Parsers VC has collected 8 articles mentioning Novitas Capital, among them “Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M” (Dec 17, 2012) and “Early Stage East: 25 startups pitch at 15th year of regional showcase [VIDEO]” (Oct 5, 2012).
Is Novitas Capital still active?
Yes, Novitas Capital is active; its latest activity on Parsers VC dates from Jun 5, 2014.